Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Trial Identifier: VAV00019
Sponsor: Sanofi Pasteur, a Sanofi Company
Start Date: April 2023
Primary Completion Date: March 2024
Study Completion Date: March 2024
Condition: Influenza Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AUSTRALIA Adelaide, AUSTRALIA, 5000
AUSTRALIA, Queensland Herston, Queensland, AUSTRALIA, 4006
AUSTRALIA, Queensland Morayfield, Queensland, AUSTRALIA, 4506
AUSTRALIA, Victoria Camberwell, Victoria, AUSTRALIA, 3124
UNITED KINGDOM, Leicestershire Leicester, Leicestershire, UNITED KINGDOM, LE1 5WW
UNITED KINGDOM, London, City of London, London, City of, UNITED KINGDOM, W12 0HS
UNITED KINGDOM, London, City of London, London, City of, UNITED KINGDOM, SW10 9NH
UNITED KINGDOM, Sheffield Sheffield, UNITED KINGDOM, S10 2JF